May 7 (UPI) -- U.S. regulators have cleared a potential COVID-19 vaccine developed by Moderna Therapeutics for a second phase of clinical trials, officials said Thursday.
The Food and Drug Administration said it's completed its phase-one safety review for Moderna's mRNA-1273 vaccine candidate and has authorized the start of a second stage study, the company said in a quarterly financial statement.